Page 11 - கேம்பிரிட்ஜ் ஒன்றுபட்டது கிஂக்டம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Posted on 259 Shanghai Stock Exchange listed biotech company HitGen Inc. (“HitGen”) announced important research progress in a collaboration with BioAge Labs, Inc. (“BioAge”), a private biotechnology company developing targeted small molecules for the treatment of diseases of aging. The companies have conducted collaborative research to identify and develop novel small-molecule compounds against a high-value and challenging biological target that is a critical component of the innate immune system. Dysregulation of this target is closely linked to the underlying cause of severe diseases in elderly humans, such as Alzheimer’s and cardiovascular disease. HitGen is a world leader in the development and applications of DNA encoded library (DEL) screening. The availability of over 1 trillion small molecules generated by DEL technology and the efficiency of the screening process have made it possible for HitGen to e

United statesUnited kingdomPaul rubinSizhou guoKristen fortneyAndreessen horowitzJin liVernalis rd ltdHitgen incBioage labs incShanghai stock exchangeKaiser foundation hospitalsBioage labsChief executiveChief executive officerCambridge united kingdom